Group One Trading’s Citius Pharmaceuticals CTXR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-649
Closed -$1.03K 8515
2025
Q2
$1.03K Sell
649
-2,693
-81% -$2.47K ﹤0.01% 7553
2025
Q1
$4.98K Sell
3,342
-1,475
-31% -$3.53K ﹤0.01% 6650
2024
Q4
$19.3K Buy
4,817
+3,991
+483% +$26.9K ﹤0.01% 5711
2024
Q3
$10.3K Sell
826
-128
-13% -$2.15K ﹤0.01% 5588
2024
Q2
$13.9K Buy
954
+171
+22% +$3.06K ﹤0.01% 5453
2024
Q1
$17.6K Sell
783
-241
-24% -$4.4K ﹤0.01% 5523
2023
Q4
$19.4K Hold
1,024
﹤0.01% 5771
2023
Q3
$17.5K Buy
+1,024
New +$24.3K ﹤0.01% 5979
2023
Q2
Sell
-1,956
Closed -$64.4K 7725
2023
Q1
$57.2K Sell
1,956
-423
-18% -$12.2K ﹤0.01% 4751
2022
Q4
$47K Buy
2,379
+652
+38% +$17.8K ﹤0.01% 5043
2022
Q3
$52K Buy
+1,727
New +$47.5K ﹤0.01% 5377

Other funds holding CTXR

Group One Trading's CTXR Position: Q3 2025 in Review

Group One Trading sold out of Citius Pharmaceuticals (CTXR) in Q3 2025, closing a stake of 649 shares — an estimated $1.03K sold.

Group One Trading first reported a position in CTXR in Q3 2022 and held it in 11 quarters. The position peaked at $57.2K in Q1 2023. 34 funds tracked by Wall St. Rank hold CTXR as of Q3 2025.

  • Group One Trading reported no remaining Citius Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Group One Trading sold 649 Citius Pharmaceuticals shares in Q3 2025, an estimated $1.03K.
  • Group One Trading first reported a position in Citius Pharmaceuticals in Q3 2022 and held it in 11 quarters.
  • Group One Trading's Citius Pharmaceuticals position peaked at $57.2K in Q1 2023.
  • 34 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2025.

Based on Group One Trading's 13F filing for Q3 2025, filed 12 Nov 2025.